14 results
Here is a quick guide on the common direct-acting antivirals (DAAs) for chronic hepatitis C virus
DAAs #Antivirals #table ... infectiousdisease #hepatology ... HepC #HepatitisC #Management ... #Pharmacology
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
body mass index; VTE ... #DOAC #VTE #Malignancy ... Anticoagulation #Management ... #Hematology #Oncology
Myelodysplastic Syndrome (MD) - Diagnosis and Management Summary
myelo (marrow) -dys- (abnormal) -plastic (shape) = funny-shaped cells
Myelodysplastic Syndrome ... Diagnosis and Management ... Myelodysplastic #Syndrome ... #treatment #hematology ... #oncology
Treatment algorithm for VTE in Malignancy

(A) Suggested treatment algorithm for symptomatic and incidental DVT or PE
algorithm for VTE ... risk of recurrent VTE ... #DOAC #VTE #Malignancy ... Anticoagulation #Management ... #Hematology #Oncology
Managing warfarin INR

Warfarin dosage must be individualized according to the patient's response to the drug, and
#management #algorithm ... #pharmacology # ... #medications #table ... decisionaid #cardiology #hematology
Behcet's Syndrome - Treatment
Ulcers:
 • Treatment: Topical steroids
 • Prevention: Colchicine
 • Azathioprine for refractory disease
Arthritis:
Behcet's Syndrome ... azathioprine (for post. uveitis ... #Treatment #management ... #pharmacology # ... rheumatology
REBEL Review 90: Weight Based 4 Factor PCC Dosing 

#Hematology #Management #Table #4FactorPCC #REBELReview #Pharmacology #Dosing
PCC Dosing #Hematology ... #Management #Table ... #REBELReview #Pharmacology
Behçet's Syndrome
Systemic disease associated with inflammation of multiple organs, small-vessel vasculitis and large-vessel vasculopathy
Epidemiology:
 • Young
sinus thrombosis, VTE ... Eye involvement (uveitis ... inhibitors • Uveitis ... #diagnosis #management ... signs #symptoms #rheumatology
(DOAC interactions) Cancer-treatment specific inducers (↑) and inhibitors (↓)
of cytochrome p450 CYP3A4 and P-glycoprotein.

DOACs are substrates
#Chemotherapy #Oncology ... #Hematology #Interactions ... #Table #Pharmacology
Differentiation Syndrome in APML
Epidemiology:
 • Incidence: common in APL (2-48% depending on the study)
 • Triggers:
Differentiation Syndrome ... Differentiation #Syndrome ... APML #diagnosis #management ... #hematology #oncology